These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 8730399)
21. [Restenosis after percutaneous transluminal coronary angioplasty and its prevention]. Przewłocka-Kosmala M; Kosmala W Przegl Lek; 1999; 56(10):671-5. PubMed ID: 10695384 [TBL] [Abstract][Full Text] [Related]
22. The good, the bad, and the ugly: triple therapy after PCI in patients requiring chronic anticoagulation. Sinnaeve PR Eur Heart J; 2007 Mar; 28(6):657-8. PubMed ID: 17332009 [No Abstract] [Full Text] [Related]
23. Combination antiplatelet therapy following brachytherapy with restenting: it ain't over 'til the fat lady sings. Kereiakes DJ; Choo JK; Young JJ; Broderick TM J Invasive Cardiol; 2002 Mar; 14(3):115-7. PubMed ID: 11870264 [No Abstract] [Full Text] [Related]
24. Harnessing the platelet. Futterman LG; Lemberg L Am J Crit Care; 1997 Sep; 6(5):406-14. PubMed ID: 9283679 [TBL] [Abstract][Full Text] [Related]
25. CardioPulse: Platelet inhibitors and their differences. Gurbel PA; Tantry US Eur Heart J; 2016 Jan; 37(4):323-6. PubMed ID: 26795932 [No Abstract] [Full Text] [Related]
26. Platelet interactions as therapeutic targets for prevention of atherothrombosis. Smid J; Braun-Dullaeus R; Gawaz M; Langer HF Future Cardiol; 2009 May; 5(3):285-96. PubMed ID: 19450054 [TBL] [Abstract][Full Text] [Related]
28. Early and late ischemic complications of PTCA. Ferguson JJ; Wilson JM J Invasive Cardiol; 1994; 6 Suppl A():3A-12A, discussion 43A-45A. PubMed ID: 10155092 [No Abstract] [Full Text] [Related]
29. [Restenosis and arterial remodelling after coronary angioplasty]. Jørgensen B; Forfang K Tidsskr Nor Laegeforen; 1996 Aug; 116(20):2460-3. PubMed ID: 8928109 [TBL] [Abstract][Full Text] [Related]
35. [Edge effect and late thrombosis -- inevitable complications of vascular brachytherapy?]. Schiele TM; Staber L; Kantlehner R; Pöllinger B; Dühmke E; Theisen K; Klauss V Z Kardiol; 2002 Nov; 91(11):869-78. PubMed ID: 12442189 [TBL] [Abstract][Full Text] [Related]
36. Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives. Ducrocq G; Serebruany V; Tanguay JF Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):939-53. PubMed ID: 17867923 [TBL] [Abstract][Full Text] [Related]
37. Late stent thrombosis with drug-eluting stents: the price to pay to prevent restenosis? Kumbhani DJ; Bavry AA; Bhatt DL Indian Heart J; 2007; 59(2 Suppl B):B113-7. PubMed ID: 19153427 [TBL] [Abstract][Full Text] [Related]
38. Platelet function assessment to predict outcomes after coronary interventions: hype or hope? Alfonso F; Angiolillo DJ J Am Coll Cardiol; 2006 Nov; 48(9):1751-4. PubMed ID: 17084244 [No Abstract] [Full Text] [Related]
39. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Cesari F; Marcucci R; Caporale R; Paniccia R; Romano E; Gensini GF; Abbate R; Gori AM Thromb Haemost; 2008 May; 99(5):930-5. PubMed ID: 18449424 [TBL] [Abstract][Full Text] [Related]
40. Molecular and cellular basis of restenosis after percutaneous coronary intervention: the intertwining roles of platelets, leukocytes, and the coagulation-fibrinolysis system. Lee MS; David EM; Makkar RR; Wilentz JR J Pathol; 2004 Aug; 203(4):861-70. PubMed ID: 15258987 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]